SECsense Logo

EDAP TMS S.A. Reports Record Q4 2024 Sales & U.S. Market Growth Insights

$EDAP
Form 6-K
Filed on: 2025-01-13
Source
EDAP TMS S.A. Reports Record Q4 2024 Sales & U.S. Market Growth Insights

Here are the key insights extracted from the financial report (Form 6-K) for EDAP TMS S.A. dated January 13, 2025:

  1. Company Overview:
  • Name: EDAP TMS S.A.
  • Location: Parc Activite La Poudrette Lamartine, 4/6 Rue du Dauphine, 69120 Vaulx-en-Velin, France.
  • Regulatory Filing: The company is filing under Form 20-F for annual reports.
  1. Financial Performance:
  • Record Sales: EDAP reported preliminary record sales for the fourth quarter of 2024, specifically 11 Focal One Systems sold globally.
  • U.S. Market Growth: There was a record number of Focal One procedures conducted in the U.S., showing a year-over-year growth of 30%.
  • CEO Statement: Ryan Rhodes emphasized the growing adoption of their Focal One Robotic HIFU (High-Intensity Focused Ultrasound) technology, suggesting that it is becoming a mainstream treatment for prostate cancer.
  1. Market Dynamics:
  • The company anticipates ongoing growth in the adoption of their technology within urology practices, particularly for prostate cancer treatment.
  1. Future Expectations:
  • EDAP plans to release final fourth-quarter financial results in March 2025.
  • The company notes that preliminary information is subject to completion of quarter-end financial reporting processes.
  1. Risks and Forward-Looking Statements:
  • The report includes forward-looking statements about future performance and market conditions. It highlights potential risks that could affect actual results, including market acceptance of their technology and macroeconomic factors such as inflation and geopolitical instability.
  • The company warns that there can be no assurance that anticipated events will occur or that objectives will be achieved.
  1. Investor Relations Contacts:
  • Blandine Confort: Investor Relations / Legal Affairs, EDAP TMS SA (+33 4 72 15 31 50, bconfort@edap-tms.com).
  • John Fraunces: LifeSci Advisors, LLC (917-355-2395, jfraunces@lifesciadvisors.com).

This information suggests a robust performance for EDAP TMS S.A. in the fourth quarter of 2024, with strong growth indicators for its Focal One product in the U.S. market, alongside a cautious outlook regarding future uncertainties.